17,261 trials
Tetralogy of Fallot (TOF) · Ventricular Septal Defects (VSD) · Atrioventricular Septal Defects (AVSD)
Primary: ACTH and Cytokine Levels — 116.9; 182.7; 135.3; 44.5 pg/mL
Autosomal Dominant Polycystic Kidney Disease
Primary: Total Kidney Volume — 1500.5; 1573.1; 1567.9; 1729.4 mL
Multiple Myeloma
Primary: The Number of Patients That Achieve Complete Response — 7 Participants
Non-hodgkin's Lymphoma · Mantle Cell Lymphoma
Primary: Maximum Tolerated Dose (MTD) of Bortezomib — 1.5; 1.0 mg/m²
Carcinoma, Small Cell · Small Cell Lung Cancer
Primary: Objective Response Rate — 3 Participants
Clostridium Difficile
Primary: Number of Subjects With CDI Recurrence — 26; 16 participants
Lymphoma
Primary: Overall Response Rate (Complete or Partial Response) by Month 12 — 60; 84 percentage of patients
Pain, Postoperative
Primary: Patient Morphine Equivalent Consumption — 35.1; 50.5; 28.0; 29.6 mg
Dry Eye Syndromes
Primary: Change From Baseline (Visit 1) in Total Corneal Fluorescein Staining at 113 Days — -2.38; -2.10; -1.69 units on a scale
Depression
Primary: Change From Baseline in Depression Symptoms on the Hamilton Depression Rating Scale 21 (HDRS-21) AT WEEK 6 — -0.4; -12.7 units on a scale — p=0.001
Human Immunodeficiency Virus (HIV)
Primary: Number of Participants Experiencing Any Grade 2 or Higher AEs During Injection Phase — 59; 31 Participants
Asthma, Aspirin-Induced · Aspirin Exacerbated Asthma
Primary: Difference in PD2 (Provocative Dose of Aspirin That Elicits an Increase in Nasal Symptom Score of 2 During an Aspirin Challenge) on Prasugrel Versus Placebo — 79; 139 mg
Adenocarcinoma of the Gastroesophageal Junction · Esophageal Cancer
Primary: Comparison of Progression-free Survival — 6.1; 2.4 Months — p=0.43
Rapidly Escalating Migraine
Primary: The Percentage of Subjects Reporting Pain Freedom at 60 Minutes Post-treatment — 50; 52.63 Percentage of responders
Adult Acute Megakaryoblastic Leukemia (M7) · Adult Acute Minimally Differentiated Myeloid Leukemia (M0) · Adult Acute Monoblastic Leukemia (M5a)
Primary: Inhibition of NF-kB Target Transcripts and/or Inhibition of Drug Efflux in at Least 50% of Patients — 13; 14 Participants — p=<.05